sulfasalazine has been researched along with Disease Exacerbation in 76 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine)." | 9.17 | Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. ( Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK, 2013) |
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 9.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 9.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| " This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid arthritis over a two year follow up period." | 9.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 9.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine." | 9.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 9.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 7.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| "To develop a population model describing the disease activity (DAS28) time course in patients with early rheumatoid arthritis (RA) treated with triple disease-modifying anti-rheumatic drug (DMARD) therapy (methotrexate, sulfasalazine and hydroxychloroquine)." | 7.81 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. ( Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J, 2015) |
| " We collected clinical information, including patient background, treatment efficacy (evaluated using the DAS score), and adverse events observed." | 5.38 | Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. ( Amano, H; Kageyama, M; Kempe, K; Kusaoi, M; Matsudaira, R; Matsushita, M; Morimoto, S; Nawata, M; Ogasawara, M; Onuma, S; Sekiya, F; Tada, K; Takasaki, Y; Tamura, N; Toyama, S; Yamaji, K, 2012) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 5.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| "Treatment with sulfasalazine correlated positively with BMD at 3 of the 5 measured bone sites." | 5.31 | Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. ( Hafström, I; Tengstrand, B, 2002) |
| "610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of prednisone." | 5.19 | A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. ( Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV, 2014) |
| "To compare 1-year clinical efficacy of (1) initial triple disease-modifying antirheumatic drug therapy (iTDT) with initial methotrexate (MTX) monotherapy (iMM) and (2) different glucocorticoid (GC) bridging therapies: oral versus a single intramuscular injection in early rheumatoid arthritis." | 5.19 | Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. ( de Jong, PH; de Sonnaville, PB; Gerards, AH; Han, HK; Hazes, JM; Huisman, M; Luime, JJ; van der Lubbe, PA; van Krugten, MV; van Schaeybroeck, B; van Zeben, D; Weel, AE, 2014) |
| "In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine)." | 5.17 | Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. ( Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK, 2013) |
| "Early treatment of patients with rheumatoid arthritis (RA) with combination treatment starting with methotrexate, sulfasalazine, hydroxychloroquine and prednisolone (FIN-RACo strategy) is superior to monotherapy." | 5.17 | Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). ( Blåfield, H; Hannonen, PJ; Ilva, K; Julkunen, HA; Kaipiainen-Seppänen, O; Karjalainen, A; Kauppi, MJ; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luosujärvi, R; Luukkainen, R; Moilanen, E; Möttönen, T; Paimela, L; Puolakka, K; Uutela, T, 2013) |
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 5.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 5.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| "Progression of radiographic damage and association of radiographic damage and genetic predisposition were compared in two cohorts, one treated according to the delayed treatment strategy (initial treatment with analgesics), the other treated according to the early treatment strategy (treatment with disease modifying antirheumatic drugs (DMARDs) chloroquine or sulfasalazine)." | 5.11 | Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. ( Breedveld, FC; Hazes, JM; Huizinga, TW; Lard, LR; le Cessie, S; van Aken, J, 2004) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | 5.09 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| " This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid arthritis over a two year follow up period." | 5.09 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Nash, P; Oed, C; Schattenkirchner, M; Scott, DL; Smolen, JS; van de Putte, LB, 2001) |
| "Between 1993 and 1995, 109 patients diagnosed with probable or definite rheumatoid arthritis of recent onset were initially treated with analgesics; if they had persistent active disease, they were treated subsequently with the disease-modifying drugs chloroquine or salazopyrine (delayed treatment)." | 5.09 | Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. ( Breedveld, FC; Hazes, JM; Lard, LR; Speyer, I; vander Horst-Bruinsma, IE; Visser, H; Zwinderman, AH, 2001) |
| "Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine." | 5.09 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. ( Kalden, JR; Kvien, TK; Larsen, A; Loew-Friedrich, I; Oed, C; Rosenburg, R; Rozman, B; Scott, DL; Smolen, JS, 1999) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 5.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "Although oral mesalamine is the first-choice drug for treating mild-to-moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain." | 4.02 | Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. ( Fujiwara, A; Higashi, R; Hiraoka, S; Inokuchi, T; Kato, J; Matsueda, K; Miyaike, J; Moritou, Y; Okada, H; Suzuki, S; Takagi, S; Takahara, M; Toyokawa, T, 2021) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 3.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| "To develop a population model describing the disease activity (DAS28) time course in patients with early rheumatoid arthritis (RA) treated with triple disease-modifying anti-rheumatic drug (DMARD) therapy (methotrexate, sulfasalazine and hydroxychloroquine)." | 3.81 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. ( Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J, 2015) |
| "Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years." | 2.75 | Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. ( Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V, 2010) |
| " Patients were treated with a dosage of 50 mg/kg/day of SSZ (maximum 2,000 mg/day) or placebo." | 2.69 | Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. ( Dijkmans, BA; Dijkstra, PF; Fiselier, TJ; Franssen, MJ; Kuis, W; Oostveen, JC; ten Cate, R; van Ede, CF; van Luijk, WH; van Rossum, MA; van Soesbergen, RM; van Suijlekom-Smit, LW; Wulffraat, NM; Zwinderman, AH, 1998) |
| "Sulfasalazine was not well tolerated in patients with PsA in our clinic." | 2.69 | The use of sulfasalazine in psoriatic arthritis: a clinic experience. ( Cook, RJ; Gladman, DD; Rahman, P; Young, G; Zhou, Y, 1998) |
| "Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists." | 2.61 | AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. ( Binion, DG; Feuerstein, JD; Singh, S; Tremaine, WJ, 2019) |
| "This paper reviews recent approaches to treatment of early rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs)." | 2.44 | Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. ( Sizova, L, 2008) |
| " The underlying mechanism for TL-118-treatment success was associated with hepatic perfusion attenuation resulting from reduced nitric-oxide (NO) serum levels as elucidated by using hemodynamic response imaging (HRI, a functional MRI combined with hypercapnia and hyperoxia)." | 1.38 | Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. ( Abramovitch, R; Corchia, N; Edrei, Y; Gross, E, 2012) |
| " We collected clinical information, including patient background, treatment efficacy (evaluated using the DAS score), and adverse events observed." | 1.38 | Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. ( Amano, H; Kageyama, M; Kempe, K; Kusaoi, M; Matsudaira, R; Matsushita, M; Morimoto, S; Nawata, M; Ogasawara, M; Onuma, S; Sekiya, F; Tada, K; Takasaki, Y; Tamura, N; Toyama, S; Yamaji, K, 2012) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 1.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| " Accordingly, noninvasive, serial quantification of colonic inflammation could advantageously guide dosing regimens and assess drug efficacy, thus enhancing the value of colitis models in research." | 1.35 | Progression and variability of TNBS colitis-associated inflammation in rats assessed by contrast-enhanced and T2-weighted MRI. ( Hobson, AR; James, MF; Kruidenier, L; Lewis, HD; McCleary, S; Pohlmann, A; Robinson, A; Tilling, LC; Warnock, LC; Woolmer, O, 2009) |
| "Treatment with sulfasalazine correlated positively with BMD at 3 of the 5 measured bone sites." | 1.31 | Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. ( Hafström, I; Tengstrand, B, 2002) |
| "A small group of patients with ulcerative colitis (UC) also suffer from primary sclerosing cholangitis (PSC)." | 1.30 | Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. ( Broomé, U; Lundqvist, K, 1997) |
| "The 'aggressive' drug treatment consisted of institution of relatively fast-acting disease-modifying anti-rheumatic drugs (DMARDs) (sulphasalazine, methotrexate) immediately after diagnosis, and rapid adjustment of dosage and/or drug in the case of insufficient response as measured by a change in C-reactive protein (CRP) level." | 1.30 | Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. ( Barendsen, BC; Bruyn, GA; Houtman, PM; Speerstra, F; Stenger, AA; Van Leeuwen, MA; van Rijswijk, MH; Velthuysen, E, 1998) |
| "Spontaneous colitis and colon cancer in the cotton-top tamarin have been shown to resemble human ulcerative colitis and its associated cancer." | 1.29 | A prospective study of the epidemiology of colitis and colon cancer in cotton-top tamarins (Saguinus oedipus). ( Ausman, LM; Johnson, LD; King, NW; Sehgal, PK, 1996) |
| "Sulfasalazine was more frequently needed in the treatment of patients with gut inflammation with a beneficial effect on articular and intestinal evolution but did not prevent evolution to IBD." | 1.29 | Long-term evolution of gut inflammation in patients with spondyloarthropathy. ( Cuvelier, C; De Vos, M; Elewaut, A; Mielants, H; Veys, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (14.47) | 18.2507 |
| 2000's | 24 (31.58) | 29.6817 |
| 2010's | 39 (51.32) | 24.3611 |
| 2020's | 2 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Man, S | 1 |
| Ji, X | 1 |
| Wang, Y | 1 |
| Ma, Y | 1 |
| Hu, Z | 1 |
| Zhu, J | 1 |
| Zhang, J | 1 |
| Huang, F | 1 |
| Hiraoka, S | 1 |
| Fujiwara, A | 1 |
| Toyokawa, T | 1 |
| Higashi, R | 1 |
| Moritou, Y | 1 |
| Takagi, S | 1 |
| Matsueda, K | 1 |
| Suzuki, S | 1 |
| Miyaike, J | 1 |
| Inokuchi, T | 1 |
| Takahara, M | 1 |
| Kato, J | 1 |
| Okada, H | 1 |
| Konijn, NPC | 1 |
| van Tuyl, LHD | 2 |
| Boers, M | 9 |
| den Uyl, D | 1 |
| Ter Wee, MM | 1 |
| van der Wijden, LKM | 1 |
| Bultink, IEM | 1 |
| Kerstens, PJSM | 1 |
| Voskuyl, AE | 2 |
| van Schaardenburg, D | 1 |
| Nurmohamed, MT | 1 |
| Lems, WF | 4 |
| Wabe, N | 1 |
| Wojciechowski, J | 2 |
| Wechalekar, MD | 2 |
| Cleland, LG | 2 |
| McWilliams, L | 2 |
| Lee, A | 1 |
| Proudman, S | 1 |
| Wiese, MD | 3 |
| Bergstra, SA | 2 |
| Landewé, RBM | 1 |
| Huizinga, TWJ | 2 |
| Allaart, CF | 11 |
| Kuijper, TM | 1 |
| Luime, JJ | 2 |
| Xiong, H | 1 |
| de Jong, P | 1 |
| van der Lubbe, P | 1 |
| van Zeben, D | 2 |
| Tchetverikov, I | 1 |
| Hazes, J | 1 |
| Weel, A | 1 |
| Akdemir, G | 2 |
| Heimans, L | 4 |
| Goekoop, RJ | 3 |
| van Oosterhout, M | 3 |
| van Groenendael, JHLM | 1 |
| Peeters, AJ | 4 |
| Steup-Beekman, GM | 2 |
| Lard, LR | 4 |
| de Sonnaville, PBJ | 1 |
| Grillet, BAM | 1 |
| Imai, R | 1 |
| Jinta, T | 1 |
| Suina, K | 1 |
| Tsuchihashi, K | 2 |
| Yamasaki, J | 1 |
| Kamenori, S | 1 |
| Shintani, S | 1 |
| Hirata, Y | 1 |
| Okazaki, S | 1 |
| Sampetrean, O | 1 |
| Baba, E | 1 |
| Akashi, K | 1 |
| Mitsuishi, Y | 1 |
| Takahashi, F | 1 |
| Takahashi, K | 1 |
| Saya, H | 2 |
| Nagano, O | 2 |
| Singh, S | 1 |
| Feuerstein, JD | 1 |
| Binion, DG | 1 |
| Tremaine, WJ | 1 |
| Poppelaars, PBM | 1 |
| Rezaei, H | 2 |
| Saevarsdottir, S | 4 |
| Geborek, P | 4 |
| Petersson, IF | 3 |
| van Vollenhoven, RF | 7 |
| Forslind, K | 6 |
| Curtis, JR | 2 |
| McVie, T | 1 |
| Mikuls, TR | 2 |
| Reynolds, RJ | 1 |
| Navarro-Millán, I | 1 |
| O'Dell, J | 1 |
| Moreland, LW | 2 |
| Bridges, SL | 2 |
| Ranganath, VK | 2 |
| Cofield, SS | 2 |
| O'Dell, JR | 1 |
| Wevers-de Boer, KV | 2 |
| Visser, K | 3 |
| Harbers, JB | 2 |
| Bijkerk, C | 2 |
| Speyer, I | 2 |
| de Buck, MP | 2 |
| de Sonnaville, PB | 4 |
| Grillet, BA | 3 |
| Huizinga, TW | 10 |
| Wada, T | 1 |
| Ishimoto, T | 1 |
| Seishima, R | 1 |
| Yoshikawa, M | 1 |
| Oshima, H | 1 |
| Oshima, M | 1 |
| Masuko, T | 1 |
| Wright, NA | 1 |
| Furuhashi, S | 1 |
| Hirashima, K | 1 |
| Baba, H | 1 |
| Kitagawa, Y | 1 |
| Kälvesten, J | 1 |
| Steup-Beekman, M | 1 |
| Petersson, I | 1 |
| Ernestam, S | 2 |
| Albertsson, K | 2 |
| de Jong, PH | 1 |
| Hazes, JM | 3 |
| Han, HK | 1 |
| Huisman, M | 1 |
| van der Lubbe, PA | 3 |
| Gerards, AH | 2 |
| van Schaeybroeck, B | 1 |
| van Krugten, MV | 1 |
| Weel, AE | 1 |
| Hambardzumyan, K | 1 |
| Bolce, R | 1 |
| Cruickshank, SE | 1 |
| Sasso, EH | 1 |
| Chernoff, D | 1 |
| Markusse, IM | 1 |
| de Vries-Bouwstra, JK | 4 |
| Han, KH | 2 |
| Schouffoer, AA | 1 |
| Kerstens, PJ | 4 |
| Proudman, SM | 2 |
| Foster, DJ | 1 |
| Upton, RN | 1 |
| Kastbom, A | 1 |
| Karlsson, JA | 1 |
| Klareskog, L | 3 |
| Lundberg, K | 1 |
| van Nies, JA | 1 |
| Tsonaka, R | 1 |
| Gaujoux-Viala, C | 1 |
| Fautrel, B | 1 |
| van der Helm-van Mil, AH | 1 |
| Levitsky, A | 1 |
| Boer, KV | 1 |
| Goekoop-Ruiterman, YP | 4 |
| Molenaar, ET | 1 |
| van Groenendael, JH | 1 |
| Wabe, NT | 1 |
| Sorich, MJ | 1 |
| Lee, AT | 1 |
| Spargo, LD | 1 |
| Metcalf, RG | 1 |
| Hall, C | 1 |
| Sizova, L | 1 |
| van der Kooij, SM | 2 |
| Güler-Yüksel, M | 2 |
| Zwinderman, AH | 4 |
| de Beus, WM | 1 |
| Ronday, HK | 3 |
| Breedveld, FC | 4 |
| Dijkmans, BA | 7 |
| Pohlmann, A | 1 |
| Tilling, LC | 1 |
| Robinson, A | 1 |
| Woolmer, O | 1 |
| McCleary, S | 1 |
| Kruidenier, L | 1 |
| Warnock, LC | 1 |
| Lewis, HD | 1 |
| Hobson, AR | 1 |
| James, MF | 1 |
| Yukawa, N | 1 |
| Mimori, T | 1 |
| van Tuyl, LH | 1 |
| Landewé, RB | 1 |
| Han, H | 1 |
| van der Linden, S | 4 |
| van de Laar, M | 1 |
| Westhovens, R | 2 |
| van Denderen, JC | 1 |
| Westedt, ML | 1 |
| Jacobs, P | 1 |
| van de Brink, H | 1 |
| Robe, PA | 2 |
| Martin, DH | 1 |
| Nguyen-Khac, MT | 1 |
| Artesi, M | 1 |
| Deprez, M | 2 |
| Albert, A | 2 |
| Vanbelle, S | 1 |
| Califice, S | 1 |
| Bredel, M | 1 |
| Bours, V | 2 |
| He, C | 1 |
| Zhang, SL | 1 |
| Hu, CJ | 1 |
| Tong, DW | 1 |
| Li, YZ | 1 |
| Svensson, B | 1 |
| Hafström, I | 2 |
| Tarkowski, A | 1 |
| Bokarewa, M | 1 |
| Klarenbeek, NB | 2 |
| Rantalaiho, V | 1 |
| Korpela, M | 2 |
| Laasonen, L | 2 |
| Kautiainen, H | 2 |
| Järvenpää, S | 1 |
| Hannonen, P | 1 |
| Leirisalo-Repo, M | 3 |
| Blåfield, H | 2 |
| Puolakka, K | 2 |
| Karjalainen, A | 2 |
| Möttönen, T | 2 |
| Suzuki, T | 2 |
| Ishihara, K | 1 |
| Vermeer, M | 1 |
| Kuper, HH | 1 |
| Hoekstra, M | 1 |
| Haagsma, CJ | 1 |
| Posthumus, MD | 1 |
| Brus, HL | 1 |
| van Riel, PL | 1 |
| van de Laar, MA | 1 |
| Ogasawara, M | 1 |
| Tamura, N | 1 |
| Kageyama, M | 1 |
| Onuma, S | 1 |
| Kusaoi, M | 1 |
| Toyama, S | 1 |
| Sekiya, F | 1 |
| Matsudaira, R | 1 |
| Nawata, M | 1 |
| Tada, K | 1 |
| Matsushita, M | 1 |
| Kempe, K | 1 |
| Amano, H | 1 |
| Morimoto, S | 1 |
| Yamaji, K | 1 |
| Takasaki, Y | 1 |
| Dirven, L | 1 |
| Ewals, JA | 2 |
| Kita, J | 1 |
| Tamai, M | 1 |
| Arima, K | 1 |
| Kawashiri, SY | 1 |
| Horai, Y | 1 |
| Iwamoto, N | 1 |
| Okada, A | 1 |
| Koga, T | 1 |
| Nakashima, Y | 1 |
| Yamasaki, S | 1 |
| Nakamura, H | 1 |
| Origuchi, T | 1 |
| Ida, H | 1 |
| Aoyagi, K | 1 |
| Uetani, M | 1 |
| Eguchi, K | 1 |
| Kawakami, A | 1 |
| Kauppi, MJ | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Luosujärvi, R | 1 |
| Luukkainen, R | 1 |
| Uutela, T | 1 |
| Ilva, K | 1 |
| Julkunen, HA | 1 |
| Paimela, L | 1 |
| Moilanen, E | 1 |
| Hannonen, PJ | 1 |
| Edrei, Y | 1 |
| Gross, E | 1 |
| Corchia, N | 1 |
| Abramovitch, R | 1 |
| Jung, YS | 1 |
| Cheon, JH | 1 |
| Park, SJ | 1 |
| Hong, SP | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| van Tuyl, L | 1 |
| van den Broek, M | 1 |
| Kostense, PJ | 1 |
| Tengstrand, B | 1 |
| Garnero, P | 2 |
| Landewé, R | 2 |
| Verhoeven, A | 1 |
| Christgau, S | 1 |
| Van Der Heijde, D | 3 |
| Boonen, A | 2 |
| Geusens, P | 2 |
| Ruderman, EM | 2 |
| van Aken, J | 1 |
| le Cessie, S | 1 |
| Wick, MC | 2 |
| Lindblad, S | 2 |
| Weiss, RJ | 2 |
| Lems, W | 1 |
| te Koppele, J | 1 |
| Weinblatt, ME | 1 |
| Issa, SN | 1 |
| van Rossum, MA | 2 |
| van Soesbergen, RM | 2 |
| Wieringa, H | 1 |
| Fiselier, TJ | 2 |
| Franssen, MJ | 2 |
| ten Cate, R | 2 |
| van Suijlekom-Smit, LW | 2 |
| Wulffraat, NM | 2 |
| van Luijk, WH | 2 |
| Oostveen, JC | 2 |
| Kuis, W | 2 |
| Martin, D | 1 |
| Chariot, A | 1 |
| Suzuki, Y | 1 |
| Wakabayashi, T | 1 |
| Saito, E | 1 |
| Suwa, A | 1 |
| Malysheva, OA | 1 |
| Wahle, M | 1 |
| Wagner, U | 1 |
| Pierer, M | 1 |
| Arnold, S | 1 |
| Häntzschel, H | 1 |
| Baerwald, CG | 1 |
| Verpoort, KN | 1 |
| Schreuder, GM | 1 |
| Terwiel, JP | 1 |
| Toes, RE | 1 |
| de Vries, RR | 1 |
| Johnson, LD | 1 |
| Ausman, LM | 1 |
| Sehgal, PK | 1 |
| King, NW | 1 |
| De Vos, M | 1 |
| Mielants, H | 1 |
| Cuvelier, C | 1 |
| Elewaut, A | 1 |
| Veys, E | 1 |
| Lundqvist, K | 1 |
| Broomé, U | 1 |
| Dijkstra, PF | 1 |
| van Ede, CF | 1 |
| Rahman, P | 1 |
| Gladman, DD | 1 |
| Cook, RJ | 1 |
| Zhou, Y | 1 |
| Young, G | 1 |
| Noseworthy, JH | 1 |
| O'Brien, P | 1 |
| Erickson, BJ | 1 |
| Lee, D | 1 |
| Sneve, D | 1 |
| Ebers, GC | 1 |
| Rice, GP | 1 |
| Auty, A | 1 |
| Hader, WJ | 1 |
| Kirk, A | 1 |
| Duquette, P | 1 |
| Carter, J | 1 |
| Francis, G | 1 |
| Metz, L | 1 |
| Shuster, E | 1 |
| Verhoeven, AC | 2 |
| Bibo, JC | 1 |
| Engel, GL | 1 |
| Stenger, AA | 1 |
| Van Leeuwen, MA | 1 |
| Houtman, PM | 1 |
| Bruyn, GA | 1 |
| Speerstra, F | 1 |
| Barendsen, BC | 1 |
| Velthuysen, E | 1 |
| van Rijswijk, MH | 1 |
| Smolen, JS | 3 |
| Kalden, JR | 2 |
| Scott, DL | 3 |
| Rozman, B | 2 |
| Kvien, TK | 3 |
| Larsen, A | 3 |
| Loew-Friedrich, I | 3 |
| Oed, C | 3 |
| Rosenburg, R | 2 |
| Lassere, M | 1 |
| Edmonds, J | 1 |
| Saudan, A | 1 |
| Sharp, JT | 1 |
| Strand, V | 1 |
| Leung, H | 1 |
| Hurley, F | 1 |
| Garcia-Porrúa, C | 1 |
| González-Gay, MA | 1 |
| González-Louzao, C | 1 |
| Castro, J | 1 |
| Rivas, MJ | 1 |
| Santos, E | 1 |
| Schattenkirchner, M | 2 |
| Rau, R | 1 |
| Tikly, M | 1 |
| van de Putte, LB | 1 |
| Nash, P | 1 |
| Visser, H | 1 |
| vander Horst-Bruinsma, IE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX[NCT00764725] | Phase 4 | 487 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis[NCT00908089] | Phase 4 | 100 participants (Actual) | Interventional | 2003-03-31 | Active, not recruiting | ||
| The Role of Gut Microbiota in the Pathogenesis of Ankylosing Spondylitis (AS), and the Effect of Fecal Microbiota Transplantation on Gut Microbiota, Gut Wall Inflammation and Clinical Activity of AS[NCT03726645] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-24 | Enrolling by invitation | ||
| Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry[NCT01399281] | 9,000 participants (Anticipated) | Observational | 2011-12-31 | Recruiting | |||
| The Effect of Tocilizumab (Anti-interleukin-6) Treatment on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients[NCT03149796] | 80 participants (Actual) | Observational | 2011-03-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for sulfasalazine and Disease Exacerbation
| Article | Year |
|---|---|
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Management; Disease Pro | 2019 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disea | 2008 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Thera | 2009 |
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; | 2013 |
Evaluation and management of psoriatic arthritis: the role of biologic therapy.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Disease Progression; Etanercept; Hu | 2003 |
Rheumatoid arthritis: more aggressive approach improves outlook.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2004 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Fa | 2004 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progres | 2007 |
Therapeutic aspects of spondyloarthropathies -- a review.
Topics: Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Infectious; Chlamydia Infections; Chlamydia | 1998 |
39 trials available for sulfasalazine and Disease Exacerbation
| Article | Year |
|---|---|
Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Adm | 2017 |
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2017 |
Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study.
Topics: Antirheumatic Agents; Anxiety; Arthritis, Rheumatoid; Depression; Disease Progression; Drug Therapy, | 2018 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression | 2018 |
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2019 |
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Absorptiometry, Photon; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthriti | 2013 |
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanerc | 2013 |
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2014 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progressi | 2015 |
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Therapy, | 2015 |
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Di | 2014 |
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Topics: Adipokines; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-React | 2015 |
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Dise | 2014 |
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antibody Specificity; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progressi | 2016 |
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-U | 2015 |
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Fema | 2016 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2009 |
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2010 |
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
Topics: Adult; Disease Progression; Early Termination of Clinical Trials; Female; Glioma; Humans; Male; Midd | 2009 |
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Bone Density; Di | 2010 |
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Finland | 2010 |
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid | 2013 |
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Collagen Type I; Collagen Type II; Disease P | 2002 |
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Epitopes | 2004 |
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; | 2004 |
Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthrography; Child; Disease Progression; Female; Humans; | 2005 |
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Disease | 2006 |
Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Di | 2008 |
Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Arthrography; Child; Child, Preschool; Diseas | 1998 |
The use of sulfasalazine in psoriatic arthritis: a clinic experience.
Topics: Adolescent; Adult; Aged; Arthritis, Psoriatic; Disease Progression; Female; Humans; Male; Middle Age | 1998 |
The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain; Canada; Disabled Persons; Disease Progression | 1998 |
Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Doub | 1998 |
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Topics: Algorithms; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; | 1999 |
Smallest detectable difference in radiological progression.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Bl | 1999 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progre | 2000 |
Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Do | 2001 |
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; C | 2001 |
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antir | 2001 |
28 other studies available for sulfasalazine and Disease Exacerbation
| Article | Year |
|---|---|
Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China.
Topics: Adult; Antirheumatic Agents; Biomarkers; Blood Sedimentation; C-Reactive Protein; China; Disease Pro | 2020 |
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis.
Topics: Abdominal Pain; Administration, Oral; Adult; Colitis, Ulcerative; Diarrhea; Disease Progression; Fem | 2021 |
Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Disease Progressi | 2017 |
Organizing pneumonia in a patient with rheumatoid arthritis with progression to usual interstitial pneumonia.
Topics: Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Disease Progression; Humans; Lung; Male; Mi | 2019 |
Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2018 |
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
Topics: Adenocarcinoma; Amino Acid Transport System y+; Animals; Biomarkers, Tumor; Cell Transformation, Neo | 2013 |
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theor | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort S | 2015 |
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Disease Progression; Dose-Respo | 2016 |
Progression and variability of TNBS colitis-associated inflammation in rats assessed by contrast-enhanced and T2-weighted MRI.
Topics: Anesthetics, Inhalation; Animals; Colitis; Colon; Contrast Media; Disease Models, Animal; Disease Pr | 2009 |
Higher levels of CCL20 expression on peripheral blood mononuclear cells of chinese patients with inflammatory bowel disease.
Topics: Adult; Aged; Biomarkers; Biomarkers, Pharmacological; C-Reactive Protein; Chemokine CCL20; China; Di | 2010 |
Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; H | 2010 |
Achilles paratendonitis as the initial manifestation of rheumatoid arthritis.
Topics: Achilles Tendon; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Disease Progr | 2011 |
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort | 2011 |
Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Disease Progression; Drug Therap | 2012 |
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive | 2012 |
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Diseases; Disease Progression; Edema; | 2013 |
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.
Topics: Angiogenesis Inhibitors; Animals; Cimetidine; Colorectal Neoplasms; Cyclophosphamide; Diclofenac; Di | 2012 |
Clinical course of intestinal Behcet's disease during the first five years.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Disease Pr | 2013 |
Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones.
Topics: Absorptiometry, Photon; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; B | 2002 |
Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Disease Progression; Feasibilit | 2005 |
Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Dose- | 2004 |
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2008 |
A prospective study of the epidemiology of colitis and colon cancer in cotton-top tamarins (Saguinus oedipus).
Topics: Adenocarcinoma; Animals; Body Weight; Campylobacter Infections; Colitis; Colonic Neoplasms; Disease | 1996 |
Long-term evolution of gut inflammation in patients with spondyloarthropathy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enteritis; Fe | 1996 |
Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cholangitis, Scleros | 1997 |
Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Pro | 1998 |
Uncommon arthritis as presenting manifestation of silent Crohn's disease.
Topics: Adult; Arthritis; Crohn Disease; Disease Progression; Female; Humans; Prednisone; Sulfasalazine; Tre | 2000 |